<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826330</url>
  </required_header>
  <id_info>
    <org_study_id>2011_21</org_study_id>
    <secondary_id>2012-A00802-41</secondary_id>
    <nct_id>NCT02826330</nct_id>
  </id_info>
  <brief_title>Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease</brief_title>
  <acronym>MAGIC</acronym>
  <official_title>Evidence of Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease: Family Studies and Relations With a Particular Genetic Profile and Serological. Comparison of Affected Individuals, Their Siblings and Healthy Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transversal multicentric French study on the microbiota in patients with Crohn's disease and&#xD;
      their first degree healthy relatives The primary objective is the comparison of microbiota&#xD;
      between patients with CD, healthy controls non genetically linked and first degree healthy&#xD;
      relatives of patients with CD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn's disease is a chronic inflammatory bowel disease associating flares and remission&#xD;
      periods. Its etiology is unknown and there are no specific therapy. CD affects young patients&#xD;
      and has a major impact on quality of life. There are few population-based studies and there&#xD;
      are about 2.5 million affected patients in Europe and North America. From data from EPIMAD&#xD;
      Registry the number of affected patients in France should be 200 000. The Crohn's disease&#xD;
      pathogenesis is bad known; It coul be the results of the activation of the gastro-intestinal&#xD;
      immune system toward gut microbiota in genetically susceptible hosts. In CD patients there is&#xD;
      an important ecologic modification of the flora with an excess of Bacteroidetes and&#xD;
      Proteobacteria and a decrease of anti inflammatory bacteria (Firmicutes). In ileum of CD&#xD;
      patients a specific E Coli (adherent and invasive E Colo) is found in two thirds of cases.The&#xD;
      presence of this AIEC seems to be associated to the variant NOD2 (results from our team in&#xD;
      multiplex families).&#xD;
&#xD;
      In a family with at least 1 patient with CD, the healthy first degree relatives present a&#xD;
      high risk (* 10) to also develop a CD.&#xD;
&#xD;
      The primary objective is the comparison of microbiota between patients with CD, healthy&#xD;
      controls non genetically linked and first degree healthy relatives of patients with CD. The&#xD;
      first endpoint is the Lachnospiraceae rates in each group.&#xD;
&#xD;
      The secondary objectives are :&#xD;
&#xD;
        1. the search for an association between bacterial dysbiosis and different genetic&#xD;
           backgrounds in patients with CD, their first degree healthy relatives and controls.&#xD;
&#xD;
        2. the quantification of potential invasive bacteria with invasive properties (E. coli&#xD;
           including adherent-invasive E. coli, Shigella, Salmonella, Yersinia, Campylobacter), and&#xD;
           fecal fungal flora (Candida albicans, in particular) and their association with genetic&#xD;
           and serological profiles in patients with CD, their healthy relatives and control&#xD;
           subjects.&#xD;
&#xD;
        3. a study of environmental risk factors using a questionnaire to be submitted to CD&#xD;
           patients, their healthy relatives and control subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2013</start_date>
  <completion_date type="Actual">April 3, 2019</completion_date>
  <primary_completion_date type="Actual">April 3, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Percentage of Lachnospiraceae bacteria in stools within 3 groups</measure>
    <time_frame>1 YEAR</time_frame>
    <description>After extraction DNA, microbiota will be studied via study of ribosomal DNA 16S using quantitative PCR and pyroséquençage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of bacteria Firmicutes phylum (including Faecalibacterium prausnitzii and Clostridium Leptum) in stools within 3 groups</measure>
    <time_frame>1 year</time_frame>
    <description>After extraction DNA, microbiota will be studied via study of ribosomal DNA 16S using quantitative PCR and pyroséquençage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define different genetic and serologic backgrounds within 3 groups</measure>
    <time_frame>1 year</time_frame>
    <description>Genetic analysis will include 380 genetic variants génétiques that will be genotyped including classic variants involved in CD: variants or mutations of NOD2, NOD1, IL23R, ATG16L1, DGL5, TNF, IL6, NFKB1... genes. Serological analysis will included anti-OmpC, anti-I2 and ASCA auto antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify of bacteria with invasive properties (including AIEC) within 3 groups</measure>
    <time_frame>1 year</time_frame>
    <description>Amplify bacterial DNA of Salmonella Typhi (amplification of ITS area specific of ARNr 16S-23S gene. For AIEC, using of qPCR methods based on chuA and yjaA genes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of environmental risk factors within 3 groups</measure>
    <time_frame>1 year</time_frame>
    <description>Specific questionnaire on environmental risk factors including vaccination, antibiotic use, ionfections, Home facilities and Diet befor the CD diagnosis</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>case Crohn disease</arm_group_label>
    <description>60 cases with Crohn's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>first relative healthy</arm_group_label>
    <description>2 healthy relatives per CD case (total 120)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>60 controls matched on gender and age with CD cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarkers</intervention_name>
    <description>fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms</description>
    <arm_group_label>case Crohn disease</arm_group_label>
    <arm_group_label>controls</arm_group_label>
    <arm_group_label>first relative healthy</arm_group_label>
    <other_name>Dysbiosis</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, saliva, stools&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Transversal multicentric French study on the microbiota in patients with Crohn's disease&#xD;
        (n=60) and their first degree healthy relatives (n=120) and controls (n=60).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient with Crohn's disease&#xD;
&#xD;
          -  Patient &gt; 18 years old&#xD;
&#xD;
          -  Having at least one first degree health relative&#xD;
&#xD;
          -  OK to participate to the project&#xD;
&#xD;
        First degree healthy relatives&#xD;
&#xD;
          -  specific clinical questionnaire and dosing fecal calprotectin to ensure the absence of&#xD;
             inflammatory pathology.&#xD;
&#xD;
          -  OK to participate to the project&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intestinal resection.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
&#xD;
          -  subject under guardianship&#xD;
&#xD;
          -  subject does not speak French&#xD;
&#xD;
          -  person unable to speak&#xD;
&#xD;
          -  taking antibiotics or bowel preparation will push 6 weeks stool specimens, after&#xD;
             cessation treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Gower-Rousseau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amiens University &amp; Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>cLERMONT fERRAND University Hospital</name>
      <address>
        <city>Clermont FERRAND</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU,Hôpital Jeanne de Flandres</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aphp Necker</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aphp St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Healthy relatives</keyword>
  <keyword>Dysbiosis</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

